2018
Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies
Sethi TK, Reddy NM. Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies. Leukemia & Lymphoma 2018, 60: 6-18. PMID: 29741421, DOI: 10.1080/10428194.2018.1466296.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAge FactorsAgedAntineoplastic Combined Chemotherapy ProtocolsBiopsyBone MarrowBrainCentral Nervous System NeoplasmsChemoradiotherapyCognitive DysfunctionCranial IrradiationFemaleHumansLymphoma, Large B-Cell, DiffuseMagnetic Resonance ImagingMiddle AgedNeoplasm Recurrence, LocalPrognosisProgression-Free SurvivalRemission InductionStem Cell TransplantationTransplantation, AutologousConceptsPrimary central nervous lymphomaDiffuse large B-cell lymphoma histologyPrimary central nervous system lymphomaAutologous stem cell transplantCentral nervous system lymphomaMulti-agent chemotherapyNervous system lymphomaStem cell transplantNon-Hodgkin lymphomaLong-term toxicityEligible patientsImmunotherapy optionsRelapsed diseaseAggressive presentationUpfront therapySystem lymphomaCell transplantFrontline treatmentPathogenetic pathwaysLymphoma histologyCurrent evidenceFrontline strategyLymphomaTherapyOngoing studies
2017
Current and Emerging Drug Therapies in Chronic Lymphocytic Leukemia
Sethi T, Reddy N. Current and Emerging Drug Therapies in Chronic Lymphocytic Leukemia. TouchREVIEWS In Oncology & Haematology 2017, 13: 34. DOI: 10.17925/ohr.2017.13.01.34.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsB cell receptorDrug therapyCLL therapyChronic lymphocytic leukemia patientsElderly unfit patientsAdditional treatment optionsDuration of treatmentRepertoire of drugsImmune effector responsesLymphocytic leukemia patientsChronic lymphocytic leukemiaLong-term toxicityUnfit patientsPatient ageCD20 antibodyRisk stratificationCLL treatmentAsymptomatic individualsTherapy optionsTreatment optionsEffector responsesLeukemia patientsLymphocytic leukemiaCLL cellsTreatment approaches